Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-((3r,4s,5r)-4-Amino-3,5-dihydroxy-hex-1-ynyl)-5-fluoro-3-[1-(3-methoxy-1h-pyrrol-2-yl)-meth-(z)-ylidene]-1,3-dihydro-indol-2-one
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the indole and oxindole chemical classes. It features a fluorinated indolinone core with an alkynyl side chain and a methoxypyrrole substituent. The molecule has been studied as an experimental inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation by controlling the transition from G1 to S phase. By inhibiting CDK2 activity—often in complex with cyclin E or A—such compounds are investigated for their potential antineoplastic effects due to their ability to halt uncontrolled cellular proliferation. This compound is not approved for clinical use and remains at the experimental research stage[1][2][3].
- Other names
- 4-alkynyl oxindole 7oCHEMBL354634CHEMBL-354634CHEMBL 354634DB03737DB-03737DB 03737(3Z)-4-[(3R,4S,5R)-4-amino-3,5-dihydroxyhex-1-ynyl]-5-fluoro-3-[ (3-methoxy -1H-pyrrol -2 -yl )methylidene ] -1 , 3-dihydro -2H-indol -2-one
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on 4-((3r,4s,5r)-4-Amino-3,5-dihydroxy-hex-1-ynyl)-5-fluoro-3-[1-(3-methoxy-1h-pyrrol-2-yl)-meth-(z)-ylidene]-1,3-dihydro-indol-2-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-((3r,4s,5r)-4-Amino-3,5-dihydroxy-hex-1-ynyl)-5-fluoro-3-[1-(3-methoxy-1h-pyrrol-2-yl)-meth-(z)-ylidene]-1,3-dihydro-indol-2-one.